Eli Lilly and Co’s diabetes drug Trulicity helped power higher-than-expected third-quarter profit on Tuesday, while sales of some other newer treatments fell short of Wall Street estimates.
Source:: Reuters – Business News
Eli Lilly and Co’s diabetes drug Trulicity helped power higher-than-expected third-quarter profit on Tuesday, while sales of some other newer treatments fell short of Wall Street estimates.
Source:: Reuters – Business News
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.